← Back to headlines
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny
4 Mar, 07:30 — 4 Mar, 07:30
Sources
Showing 1 of 1 sources
Related Stories
High HPV awareness, but barriers stall PH vaccination
just now
Baguio Health Office expands services to include eye test
just now
Half of trauma patients never fully recover, expert says
9m ago
Living with migraine: ‘I’d be sitting having a conversation and within a split second, I would lose power on my left side’
13m ago